General anesthetics

IntelliGuard Hosts Webinar with Top Anesthesiologist Dr. Jodi Kuhlman on the Dangers and Consequences of Drug Diversion

Retrieved on: 
Thursday, June 24, 2021
Opioids, Psychoactive drugs, Drugs, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Drug control law, Fentanyl, Sufentanil, Drug diversion, Heroin

As one of the top anesthesiologists in the country, Dr. Jodi Kuhlman fell victim to drug diversion, becoming addicted to sufentanil and fentanyl.

Key Points: 
  • As one of the top anesthesiologists in the country, Dr. Jodi Kuhlman fell victim to drug diversion, becoming addicted to sufentanil and fentanyl.
  • Drug diversion the act of stealing controlled substances for personal or illicit use is unfortunately a prevalent issue among healthcare systems of all sizes.
  • And if convicted, drug diversion is a criminal offense that could lead to the loss of a medical license .
  • Like myself, it is not uncommon to succumb to those pressures and fall victim to addiction," said Jodi Kuhlman, M.D.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ChemoCentryx, AcelRx, Ocugen, and Tarena and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 24, 2021
Medical specialties, Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Ethers, Sufentanil, Vasculitis, Avacopan, Fentanyl

The FDA also raised serious safety concerns with avacopan for the treatment of ANCA-associated vasculitis.

Key Points: 
  • The FDA also raised serious safety concerns with avacopan for the treatment of ANCA-associated vasculitis.
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • For more information on the Tarena class action go to: https://bespc.com/cases/TEDU
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

New High Potency Synthetic Opioid Linked to Overdose Deaths Across United States

Retrieved on: 
Thursday, June 17, 2021
Psychoactive drugs, Drugs, Synthetic opioids, Analgesics, Anilides, Piperidines, General anesthetics, Janssen Pharmaceutica, Fentanyl, Opioid, Drug overdose, Etonitazene

WILLOW GROVE, Pa., June 17, 2021 /PRNewswire/ -- A novel synthetic opioid with purported potency greater than fentanyl has emerged in the United States and is linked to a growing number of overdose deaths across at least five states.

Key Points: 
  • WILLOW GROVE, Pa., June 17, 2021 /PRNewswire/ -- A novel synthetic opioid with purported potency greater than fentanyl has emerged in the United States and is linked to a growing number of overdose deaths across at least five states.
  • Dr. Barry Logan, Executive Director at the CFSRE, touted his laboratory's work with synthetic drugs and its growing collaborations with medical examiner and coroner offices across the United States.
  • N-Pyrrolidino etonitazene is a new high potency synthetic opioid which began appearing in the United States drug supply within the last month.
  • This increased potency means the drugs could present a high overdose risk for people using opioid drugs, and especially a high risk for those who use the drug unsuspectedly.

Fentanyl (CAS 437-38-7) Global Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021
Health, Pharmaceutical, Drugs, Anilides, Piperidines, Synthetic opioids, Pharmacology, General anesthetics, Janssen Pharmaceutica, Fentanyl, Psychoactive drugs, Drug Enforcement Administration

The "Fentanyl (CAS 437-38-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fentanyl (CAS 437-38-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Fentanyl.
  • The fifth chapter deals with Fentanyl market trends and forecast, distinguish Fentanyl manufacturers and suppliers.
  • The Fentanyl global market report key points:

Ketamine One Closes Previously Announced Acquisition of Integrated Rehab and Performance

Retrieved on: 
Tuesday, June 15, 2021
Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Antidepressants, Chloroarenes, Nicotinic antagonists, General anesthetics, Ketamine

VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (Ketamine One or the Company) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has closed its previously announced acquisition (the Acquisition) of Integrated Rehab and Performance Ltd. (IRP).

Key Points: 
  • VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (Ketamine One or the Company) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has closed its previously announced acquisition (the Acquisition) of Integrated Rehab and Performance Ltd. (IRP).
  • As consideration for the Transaction, Ketamine One issued 602,410 common shares of the Company (the Consideration Shares) at a price per common share of $1.66.
  • Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

SHAREHOLDER ALERT: Robbins LLP Announces that AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders

Retrieved on: 
Monday, June 14, 2021
Legal, Professional services, Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Analgesics, Ethers, Sufentanil, Fentanyl

AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain.

Key Points: 
  • AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain.
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-sever acute pain.
  • If you suffered a loss due to AcelRx Therapeutics, Inc.'s misconduct, click here .
  • On February 16, 2021, AcelRx disclosed that, on February 11, 2021, the Company received a warning letter from the FDA concerning promotional claims for DSUVIA.

Ketamine One Appoints Loreto Grimaldi to Board of Directors

Retrieved on: 
Monday, June 14, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Arylcyclohexylamines, Nicotinic antagonists, General anesthetics, Sedatives, Ketamine, Loreto, Baja California Sur, Olney's lesions, Loreto

Mr. Grimaldi brings over 25 years of corporate, transactional and governance experience to Ketamine One.

Key Points: 
  • Mr. Grimaldi brings over 25 years of corporate, transactional and governance experience to Ketamine One.
  • On behalf of the Company, I extend a warm welcome Loreto as the newest member of Ketamine Ones Board of Directors, said Rob Meister, Chief Executive Officer of Ketamine One.
  • Loreto is also the co-founder of Untether Capital Inc. dba Fleets Coffee, which is a disruptive food technology platform.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

American Journal of Psychiatry Publishes International Ketamine and Esketamine Treatment Guidance Led by Braxia Scientific CEO Dr. Roger Mcintyre

Retrieved on: 
Wednesday, June 9, 2021
Psychoactive drugs, Drugs, NMDA receptor antagonists, General anesthetics, Antidepressants, Nicotinic antagonists, Sedatives, Esketamine, Ketamine

The Guidelines were developed and led by Braxia's CEO Dr. Roger S. McIntyre, M.D., and Braxia Health Medical Director, Joshua Rosenblat, M.D., M.

Key Points: 
  • The Guidelines were developed and led by Braxia's CEO Dr. Roger S. McIntyre, M.D., and Braxia Health Medical Director, Joshua Rosenblat, M.D., M.
  • Both Esketamine and intravenous (IV) Ketamine are the first glutamate-based treatments demonstrated to be rapidly effective in adults suffering from TRD.
  • "We have been encouraged to see increased availability and access to esketamine and ketamine for adults experiencing TRD.
  • We have been equally interested to assure that implementation of these rapid-acting treatments is conducted according to the best of science and clinical practice parameters," said Dr. Roger S. McIntyre, CEO, Braxia Scientific.

ACELRX PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AcelRx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, June 9, 2021
Legal, Professional services, Opioids, Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Ethers, Sufentanil, Fentanyl, Pain

Investors have until August 9, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until August 9, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • AcelRx is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of acute pain.
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • The complaint alleges that, throughout the Class Period, defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

Leading Psychedelic Wellness Company Delic Signs Definitive Agreement to Acquire Ketamine Infusion Centers Llc, Bringing Physical Retail Chain to Delic Portfolio

Retrieved on: 
Tuesday, June 8, 2021
Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Dissociative drugs, Sedatives, Chloroarenes, Nicotinic antagonists, Ketamine, WellPet, OTC Markets Group

VANCOUVER, BC, June 8, 2021 /PRNewswire/ -Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has signed a definitive agreement (the "Agreement") to acquire Ketamine Infusion Centers LLC ("KIC").

Key Points: 
  • VANCOUVER, BC, June 8, 2021 /PRNewswire/ -Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has signed a definitive agreement (the "Agreement") to acquire Ketamine Infusion Centers LLC ("KIC").
  • Supported by clinical trials and peer reviewed studies, ketamine infusions have emerged as a promising treatment option for chronic diseases and pain disorders.
  • We are focused on making psychedelic wellness truly accessible, and this is a huge development in the realization of that vision."
  • DELIC is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation.